Linsitinib not checked

Astellas · OSI-906

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
13 in total · 2 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“150 mg linsitinib is taken twice daily by mouth for 24 weeks”In the company’s words, NCT07753603 on ClinicalTrials.gov
Tested for
Graves Orbitopathy (2 trials), Thyroid Eye Disease, TED, Thyroid Eye Disease, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases and 5 more
Main trialPhase 3
“The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).”In the company’s words, NCT07753603 on ClinicalTrials.gov
Other names
OSI-906

Other drugs for Graves Orbitopathy

All 17 drugs for Graves Orbitopathy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jun 2028 Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Phase 2/3Recruiting Jun 2026 Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 3Completed 11 Jul 2012 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Phase 2/3Completed 15 Oct 2024 A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2Terminated 4 Nov 2011 A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Phase 2Completed 1 Mar 2013 Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Phase 2Completed 1 Jul 2013 Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Phase 2Completed 14 Oct 2016 A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Phase 1/2Completed 1 Aug 2014 A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Phase 1Completed 20 Sep 2010 Study of Intermittent OSI-906 Dosing
Phase 1Completed 3 Mar 2012 A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Phase 1Completed 19 Mar 2012 Study of Continuous OSI-906 Dosing
Phase 1Completed 8 Dec 2012 A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Linsitinib

Following is part of Solo: you see every change to Linsitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in